| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Oxantel Pamoate targets parasitic nematodes, particularly whipworms (Trichuris species). The compound is a potent, broad-spectrum anthelmintic agent. Its mechanism of action involves paralyzing and immobilizing parasites by causing spastic paralysis, which allows the worms to be expelled from the gastrointestinal tract. Oxantel Pamoate is a veterinary anthelmintic. It has been shown to be safe and superior to single-dose albendazole and mebendazole against whipworm infection. The compound is used as an antinematodal agent.
|
|---|---|
| ln Vitro |
Oxantel Pamoate demonstrates broad-spectrum anthelmintic activity in vitro against parasitic nematodes. The compound is a potent anthelmintic agent. Its activity is assessed by standard anthelmintic susceptibility testing methods using parasitic nematode cultures. The compound's efficacy against whipworm infection has been demonstrated. Oxantel Pamoate is used as an antinematodal agent.
|
| ln Vivo |
The efficacy of Oxantel pamoate, a veterinary medication, was investigated in relation to Trichuris muris, Ancylostoma ceylonensis, and Ancylostoma americana. Oxantel pamoate's estimated ED50 against T. In mice, muris is 4.7 mg/kg. Oxantel and pyrantel pamoates demonstrated antagonistic interactions (combination index (CI) = 2.53). When combined with levamisole, albendazole, or ivermectin, oxantel pamoate had antagonistic effects at ED50 ratios (CI 1.27, 1.90, and 1.27, correspondingly). A very synergistic impact (CI=0.15) was seen in mice infected with rat caterpillars when Oxantel mebendazole pamoate was given to them. Ancylostoma americanum and Ancylostoma ceylonensis are not susceptible to oxantel pamoate (10 mg/kg) [1].
Oxantel Pamoate is used in vivo as a veterinary anthelmintic for the treatment of intestinal worm infections, particularly whipworm infections. The compound was introduced on the market in 1974. It has been shown to be safe and superior to single-dose albendazole and mebendazole against whipworm infection. The compound is administered orally. Its in vivo efficacy has been established through veterinary and human use. Oxantel Pamoate is for research use only and is not for human therapeutic use. |
| Enzyme Assay |
Oxantel Pamoate does not have established receptor binding or enzyme inhibition assay protocols. Its anthelmintic activity is assessed in whole-organism assays using parasitic nematodes. Parasitic nematode cultures are used to assess the compound's ability to inhibit worm motility and survival. Physical properties: molecular weight 604.65; molecular formula C36H32N2O7; IUPAC name: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol; appearance: solid; purity: 99% - 99.27%; storage: +5°C.
|
| Cell Assay |
Oxantel Pamoate is not evaluated in conventional cell-based assays as it is an anthelmintic. Its effects are evaluated in whole-organism assays using parasitic nematodes. Standard parasitological methods are used to assess efficacy against intestinal worms. Worm motility and survival are assessed in the presence of the compound.
|
| Animal Protocol |
In vivo efficacy of Oxantel Pamoate is evaluated in animal models of helminth infection. The compound is administered orally at doses determined by veterinary studies. Parasite burden is quantified by counting worms in the gastrointestinal tract. Clinical symptoms are monitored. The compound has been shown to be safe and superior to single-dose albendazole and mebendazole against whipworm infection. Sample sizes typically range from 6-10 animals per group. Veterinary clinical studies have been conducted for whipworm and other intestinal worm infections.
|
| ADME/Pharmacokinetics |
Molecular Weight: 604.65. Formula: C36H32N2O7 (or C23H16O6·C13H16N2O). CAS No.: 68813-55-8. Synonyms: Oxantel embonate, CP 14445-16, Telopar. Appearance: Solid. Purity: 99% - 99.27%. Storage: +5°C. Oxantel Pamoate is a potent, broad-spectrum anthelmintic compound introduced in 1974.
|
| Toxicity/Toxicokinetics |
Oxantel Pamoate is generally well-tolerated at therapeutic doses. Common adverse effects may include mild gastrointestinal disturbances. The compound is for research use only and is not for human therapeutic use.
|
| References |
[1]. Keiser J, et al. Activity of oxantel pamoate monotherapy and combination chemotherapy against Trichuris muris and hookworms: revival of an old drug. PLoS Negl Trop Dis. 2013;7(3):e2119.
|
| Additional Infomation |
Oxantel pamoate is a type of naphthoic acid.
Oxantel Pamoate is also known as Oxantel embonate, CP 14445-16, Telopar. Its IUPAC name is 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol. Oxantel Pamoate is a potent, broad-spectrum anthelmintic compound introduced in 1974. It has been shown to be safe and superior to single-dose albendazole and mebendazole against whipworm infection. Oxantel Pamoate is approved for veterinary use in many countries. |
| Molecular Formula |
C36H32N2O7
|
|---|---|
| Molecular Weight |
604.648
|
| Exact Mass |
604.22
|
| CAS # |
68813-55-8
|
| Related CAS # |
Oxantel;36531-26-7
|
| PubChem CID |
5281086
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.09 g/cm3
|
| Boiling Point |
383.1ºC at 760 mmHg
|
| Flash Point |
185.5ºC
|
| LogP |
7.417
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
45
|
| Complexity |
854
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1)O.OC5=CC=CC(/C=C/C6=NCCCN6C)=C5
|
| InChi Key |
CCOAINFUFGBHBA-UETGHTDLSA-N
|
| InChi Code |
InChI=1S/C23H16O6.C13H16N2O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-7,10,16H,3,8-9H2,1H3/b;7-6+
|
| Chemical Name |
4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-[(E)-2-(1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)ethenyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~82.69 mM)
H2O : ~0.67 mg/mL (~1.11 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (4.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (4.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (4.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6538 mL | 8.2692 mL | 16.5385 mL | |
| 5 mM | 0.3308 mL | 1.6538 mL | 3.3077 mL | |
| 10 mM | 0.1654 mL | 0.8269 mL | 1.6538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
